NEWS & EVENTS

Latest news and upcoming events

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases
14 Sep 2022

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

Upcoming events
  • Women in venture Capital Summit:Europe
    26 – 27 September 2022,
    Paris

    download
  • Brain Innovation Days
    11 – 12 October 2022,
    Brussels

    download
  • BIO-EUROPE 2022
    24 - 26 October 2022,
    Leipzig

    download
Aura Biosciences to Participate in Upcoming Investor Conferences<

Aura Biosciences to Participate in Upcoming Investor Conferences

Webcast of the Cowen fireside chat and Jefferies presentation will be available on Aura's “Investors & Media” page

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.<

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments

SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022<

SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022

Findings provide additional preclinical validation ahead of IND/CTA submission planned in Q3 2022

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results<

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

• LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancer dosed the first patients and is on track to report initial data in H2 2022

Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights<

Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

We continue to advance the AU-011 overall development program and look forward to several upcoming clinical milestones, in the second half of this year

LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies<

LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

Supported by encouraging preclinical and preliminary clinical data, we believe in the potential of LAVA-051 to address unmet patient needs.

CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System<

CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System

Heart failure patients implanted with Barostim can now receive conditional MRI scans

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference<

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer

SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022<

SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022

demonstrating a highly significant protection of visual function as well as greater cone density following subretinal administration of SPVN06 in a murine model.

Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®<

Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®

Expands Commercial coverage to 92% of total commercial lives

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.